Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
News
Renovacor Reports Second Quarter 2022 Financial Results and Provides Corporate Update
REN-001 IND submission planned for the second half of 2022
Data from pilot pig study showing successful cardiac transduction with REN-001 delivered via low-dose retrograde coronary sinus infusion published in Journal of the American College of Cardiology: Basic to Translational Science
Wellsheet Partners with athenahealth’s Marketplace Program to Improve EHR Productivity and Reduce Clinician Burnout
Concarlo Therapeutics Hires Vadim Shepel as Chief Business & Operating Officer, Completing Build-out of Company’s Core Executive Team
Senior Leader Brings Deep Biotech and Pharmaceutical Industry Experience
Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial
Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Expected in 2022
Wellsheet Recognized as a Sample Vendor in Smart EHR UI in a Gartner Report
Smart EHR UI Critical as Healthcare Burnout and Turnover Reach Record Levels, Jeopardizing Patient Care and the Bottom Line of Health Systems